Although classification of tumors into groups on the basis of PD-L1 status and the presence of TILs has been proposed for other cancer types,27,28 SCLC has not previously been evaluated for the relation between immune characteristics and clinical outcome of chemo-immunotherapy. This evidence concerns the gene CD274 and small cell lung carcinoma.